François Ferré

Dr. François Ferré is the co-CEO of ALMA Life Sciences LLC, an investment and consulting firm. He is also the co-Chairman and co-Founder of AltheaDx, a privately-held company (a spinoff of Althea Technologies) focusing on the development of pharmacogenomic tests. Dr. Ferre was the CEO of AltheaDx from 2010 to June 2013. Prior to AltheaDx, Dr. Ferré co-founded Althea Technologies and served as co-CEO from 1998 until 2008. He was a Director of Althea Technologies until April 2013 and has recently been appointed a Director of Ajinomoto-Althea after the acquisition of the company by Ajinomoto. He also currently serves on the board of a number of private companies such as Biomatrica and Portable Genomics. He is co-Chairman of the Advisory Board of MD Revolution.

Dr. Ferre is also a Trustee of the Keck Graduate Institute, Claremont CA. Dr. Ferré was the winner of the 2005 E&Y Entrepreneur of the Year award in the Life Sciences category. Dr. Ferré is a leader in gene quantification and biomarker development in the fields of AIDS and Cancer research.

In collaboration with Dr. Jonas Salk, he developed the first FDA validated quantitative PCR test for the assessment of HIV pro-viral DNA load in AIDS patients. Dr. Ferre has published several authoritative reviews on these topics, including the co-edition of a bestseller book on PCR with Nobel Prize winner, Dr. Cary Mullis. He received his Ph.D. in molecular oncology from the Pasteur Institute, France, and did his post-doctoral training at the University of California, San Diego.